Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.
Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback